These signatures include EpCAM for colorectal [65,66] and ovarian cancers [24,67], epidermal growth factor receptor (EGFR) for brain cancers [21,56] and human epidermal growth factor receptor 2 receptor (HER2/neu) for breast cancer [68]. This evidence concerns the gene ERBB2 and breast carcinoma.